Back To Her Biotech Roots: An Interview With Anna Protopapas

After almost two decades at Millennium/Takeda, Anna Protopapas moves to tiny Mersana Therapeutics, which aims to power up oncology with its Fleximer drug conjugate platform.

The 2013 launch of Genentech Inc./Roche's Kadcyla (ado-trastuzumab emtansine) for breast cancer seemed to open the door to the long-anticipated age of the armed anticancer antibodies known as antibody-drug conjugates (ADCs). Kadcyla links Roche’s first-line breast cancer therapy Herceptin (trastuzumab) to the cytotoxin, DM1, to deliver a highly targeted combo cancer killer. Oncologists and public markets alike were wowed, with Kadcyla amassing 536 million Swiss francs in its first full year of sales and capturing about 40% of the US and 30% of the EU market in second-line therapy. Roche looked to the ADC as the engine for a future blockbuster first-line breast cancer treatment franchise. Then MARIANNE showed up.

In December 2014, results from the much-anticipated MARIANNE study of Kadcyla alone, in combination with another Roche cytotoxic drug, and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Cipla Revs Up Biosimilars Engine Amid Winds Of Regulatory Change

 

Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.

With Planned US Facility Acquisition, Celltrion Looks To Avoid US Pharma Tariffs

 
• By 

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

More from Business

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.